Anadys Restructures, Focusing On Two Pipeline Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Anadys abandons its lead candidate, ANA380, with rights reverting to LG Life Sciences, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.
Anadys Resumes Work With TLR7 Drug
HCV candidate’s preclinical toxicity resolved, but investor focus is still mainly on polymerase inhibitor.
Anadys Resumes Work With TLR7 Drug
HCV candidate’s preclinical toxicity resolved, but investor focus is still mainly on polymerase inhibitor.